Mangoceuticals, Inc. announced obtaining DEA authorization for the company?s HIPAA-compliant operating system through Surescripts. This significant milestone positions MangoRx at the forefront of the direct-to-consumer (DTC) telemedicine market. Securing DEA clearance to prescribe controlled medications via Surescripts, the nation?s leading health information network, sets MangoRx apart from its competitors, validating its cutting-edge technology and regulatory compliance.

This approval aims to give MangoRx?s provider network more flexibility in prescribing custom medication and treatments to include a comprehensive range of controlled substances such as hormone replacement therapies - which they anticipate will drive significant growth in this category. The DEA approval provides a robust foundation for the company's future expansion and success, ensuring adherence to stringent regulatory standards while fostering innovation. This authorization through Surescripts will enable MangoRx to expand its offerings to include controlled substances, creating new revenue streams while allowing the company to hyperscale operations.

The advanced operating system, featuring real-time data tracking and seamless integration, sets a new benchmark for excellence in telemedicine, enhancing patient engagement and satisfaction. As MangoRx continues to redefine the DTC healthcare experience, the company are strategically positioned to significantly impact the market and drive growth. The company proprietary operating system and the DEA's endorsement signal a transformative phase for the Company.